FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
本文は利用できません。元の情報源をご確認ください。
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals